Modern Healthcare Staff
Why is the nation's capital suddenly obsessed with biomedical innovation? And why is the fruit of that obsession, the 21st Century Cures Act, moving like a greased pig through the usually deadlocked Congress—even as some experts warn it could undermine the FDA's ability to protect the public from unproven and potentially unsafe new drugs and medical devices?
Optum, a division of UnitedHealth Group, is walking away from its role overseeing the performance of HealthCare.gov. Experts say a primary focus for the government and the next contractor will be to improve the back-end systems of the website that sells insurance as part of the federal health law.
The House Energy & Commerce Committee is scheduled to hold a legislative markup session Thursday on the 21st Century Cures Act, which would overhaul federal regulation of prescription drugs and devices. Nearly every sector of the healthcare industry has gotten involved in lobbying the bill.
Connecting monitoring devices and EHRs is likely to become a growth business over the next decade. Once they do start communicating, together they could also help clinicians improve care and raise hospital productivity.
The White House has nominated Dr. Karen DeSalvo to be assistant secretary for health at HHS. If confirmed by the Senate, DeSalvo would leave her post as head of the department's Office of the National Coordinator for Health Information Technology.
Having secured a funding boost for the National Institutes of Health in the 21st Century Cures legislation, House Democrats now say the Food and Drug Administration would be ill-equipped to handle the new burdens under the bill without more resources.
A new draft of House legislation that creates significant new regulatory leeway for drug and device companies now includes more funding for the National Institutes of Health. The revised draft represents a compromise with Democrats who withdrew support for the initial bill.
The House Energy & Commerce Committee this week is expected to unveil a revised version of controversial legislation overhauling the Food and Drug Administration's regulatory process, with a hearing scheduled for Thursday. But as of late last week, there were still unresolved issues.
WASHINGTON—The CMS paid out more than $380 million in incentive payments through its Physician Quality Reporting System and electronic-prescribing incentive programs, but more than 400,000 providers chose to accept pay cuts rather than participate in the quality reporting system.